Israel has given final approval to a law permitting the export of medical marijuana, a move the government expects will catapult investment in local industry and agriculture.

The Cabinet’s decision Sunday came a month after the Israeli parliament unanimously approved the decision, making Israel the third country in the world, after the Netherlands and Canada, to allow export of medical cannabis products.

Israel is home to dozens of companies active in the medical marijuana industry, and approved companies will be able to export to countries where it is legal.

Namaste Technologies Inc. ("Namaste" or the "Company") (TSXV: N)(FRA: M5BQ)(OTCMKTS: NXTTF) is pleased to announce that further to its January 18 th, 2018 letter of intent ("LOI"), that the Company has signed a subscription agreement (the "Agreement") to acquire 10% of the issued share capital of Israeli licensed producer of medical cannabis, Cannbit Ltd ("Cannbit") for NIS 2,500,000 or approximately CAD $908,000, which includes a combination of both cash and shares.

Israel’s Together said on Thursday it signed a binding two-year deal worth at least $300 million to supply cannabis products to an unnamed Canadian company.

The Canadian firm will buy from Together subsidiary Globus Pharma 5 to 50 tonnes of dried cannabis inflorescences in 2019, which is equivalent to 500 kilograms to 5 tonnes of medical cannabis oil.

In 2020, the company, which has a licence to grow, manufacture and import medical cannabis in Canada, will buy another 20 to 50 tonnes of dried flowers, or up to 5 tonnes of cannabis oil.

It will pay at least $3 for 1 gram of dried inflorescences, or a minimum of $30,000 for 1 kg of cannabis oil, Together said.

Canada approved medical pot in 2001 and will legalize recreational use by July.

CEO Perry Davidson:  We're a hardware company, a medical devices company, for administering medical cannabis.

The capital market has been swooning recently over listed cannabis companies, especially over the as yet unfulfilled promise of marketing the product overseas. Meanwhile, while approval for exporting cannabis is being delayed, quite a few less prominent private companies are starting to fulfill their promises in the Israeli market.

66 out of 371 companies currently listed on the Canadian Securities Exchange have cannabis-related businesses.

The Canadian Securities Exchange (CSE), an alternative stock exchange in Canada, has partnered with New York-headquartered the OTC (over-the-counter) Markets Group to offer early-stage companies a new initial public offering program in North America, and they are setting their cap at Israeli startups.

According to Reuters, a deal worth up to US$235 million was recently made between Globus Pharma and an unnamed Canadian company.

Together, an Israeli pharmaceutical company just solidified plans to sell 5 tonnes of cannabis oil to an unknown Canadian company. The deal is potentially worth hundreds of millions of shekels. A Together subsidiary, Globus Pharma will be in charge of the business dealings. The Canadian company involved remains under-wraps. The arrangement will have the Canadian company purchasing 5 tonnes of cannabis oil (or 50 tonnes of dried inflorescences) per year from Globus and includes a research and development partnership to advance medical cannabis technologies.

Israel’s Together has agreed to sell 5 tonnes of cannabis oil to an unnamed Canadian company that will potentially bring revenue of hundreds of millions of shekels.

The Canadian company will buy from Together subsidiary Globus Pharma 50 tonnes of dried inflorescences of cannabis each year, which is equivalent to five tonnes of medical cannabis oil.

The two companies will also collaborate in the field of research and development and promoting technologies in the medical cannabis sector. They have estimated sales will amount to $3.17 to $4.7 per gram of inflorescence.

An Israeli company will partner with an Australian one to help boost clinical education opportunities around medical cannabis. The two companies, iCAN: Israel-Cannabis and Melbourne-based LeafCann have announced a joint-venture to collaborate on a range of initiatives including medicinal cannabis research, product development, and education.

The venture will be called iCAN: Australia, and, according to LeafCann Group CEO Jaroslav Boublik, the companies will “develop global clinical education initiatives to bridge the gap between public demand and practitioner education.”

Is marijuana good medicine for those suffering from cancer? Definitely. Even the federal government agrees that “cannabinoids may have benefits in the treatment of cancer-related side effects.” Can marijuana cure cancer? That answer remains elusive, but there are no clinical studies demonstrating that marijuana will remove cancerous tumors from the body.

CURE Pharmaceutical, a California-based technology company, revealed last month that it will be conducting a groundbreaking clinical study to test whether cannabis can kill or reduce cancerous cells.

CURE Pharmaceutical, a technologically-based drug delivery platform and its partner, Technion-Israel Institute of Technology will be conducting a clinical study to test whether cannabinoid compounds will reduce or eliminate cancerous cells.

Can cannabis really make cancer disappear?

Cannabis as a cancer treatment not only for it symptoms but as a possible cure has been hotly debated and researched for some time.